Revolution Medicines (NASDAQ:RVMD) Insider Sells $427,962.96 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Stephen Michael Kelsey sold 4,302 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the completion of the transaction, the insider owned 295,398 shares of the company’s stock, valued at $29,386,193.04. This trade represents a 1.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Revolution Medicines Trading Up 1.2%

Shares of RVMD stock traded up $1.18 during mid-day trading on Thursday, hitting $99.29. 1,485,201 shares of the company’s stock were exchanged, compared to its average volume of 2,335,170. The stock has a market cap of $19.68 billion, a price-to-earnings ratio of -16.80 and a beta of 0.99. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $124.49. The stock has a 50-day simple moving average of $103.58 and a two-hundred day simple moving average of $76.24.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period in the previous year, the firm posted ($1.12) earnings per share. Equities analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Revolution Medicines

Institutional investors have recently bought and sold shares of the business. Indiana Trust & Investment Management Co acquired a new stake in shares of Revolution Medicines in the fourth quarter worth $32,000. Global Retirement Partners LLC lifted its holdings in shares of Revolution Medicines by 1,002.8% during the 4th quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after acquiring an additional 361 shares in the last quarter. Torren Management LLC purchased a new stake in Revolution Medicines during the 4th quarter worth $33,000. Arax Advisory Partners purchased a new stake in Revolution Medicines during the 4th quarter worth $38,000. Finally, GAMMA Investing LLC increased its holdings in Revolution Medicines by 45.1% in the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after purchasing an additional 260 shares in the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RVMD shares. Evercore raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Wednesday, February 25th. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Jefferies Financial Group began coverage on shares of Revolution Medicines in a report on Monday. They issued a “buy” rating on the stock. Wedbush restated an “outperform” rating on shares of Revolution Medicines in a report on Friday, January 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.